Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caudal Nalbuphine for Emergence Agitation in Pediatrics
NCT05245721Phase 1Unknown
- Sponsor
- Assiut University
- Start
- Mar 2022
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, double-blind trial of nalbuphine in Emergence agitation (EA) and postoperative pain (2 arms), sponsored by Assiut University. Primary endpoint: Pediatric Anesthesia Emergence Delirium Scale at 2 hours. Status: unknown.
02
Drugs
nalbuphine
03
Conditions
Emergence agitation (EA)postoperative pain
Beyond the preview
Go deeper on NCT05245721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245721.